Non classé
A Shared Vision for Patient-Centred Oncology: Professor Florian Lordick Candidate for ESMO President
Professor Florian Lordick is standing for President of the European Society for Medical Oncology with a vision centred on equity, innovation, and m...
From Blood Tests to Better Decisions: GUIDE.MRD Advances the Future of Personalised Cancer Care
GUIDE.MRD partners gathered in Switzerland to advance liquid biopsy research in colorectal, pancreatic, and lung cancers. The project aims to detec...
Biosimilars, Access, and the Future of Patient Care in Europe
Biosimilars are reshaping conversations around patient access, healthcare sustainability, and resilience across Europe. At the 2026 Biosimilar Medi...
TOGAS Closes in Riga: Shaping the Future of Gastric Cancer Prevention in Europe
At the TOGAS Closing Meeting in Riga, partners from across Europe shared key findings on gastric cancer prevention and screening. DiCE highlighted ...
Rising Early-Onset Cancer: Rethinking Care for Younger Adults
Experts at TSJCI highlighted the growing burden of early-onset cancers, calling for tailored screening, multidisciplinary research, and age-appropr...
Switching Off KRAS: A Promising Breakthrough in Pancreatic Cancer Treatment
Results from the RASolute 302 phase 3 trial show the targeted drug Daraxonrasib improves survival in metastatic pancreatic cancer after prior treat...
Landmark New England Journal of Medicine (NEJM) Publication Advances Gastric Cancer Prevention
A new New England Journal of Medicine paper, led by International Agency for Research on Cancer, outlines practical guidance for Helicobacter pylor...
Unblocking Multinational Clinical Trials in Europe: Progress, but More to Do
New Clinical Trials Regulation guidance from the European Commission introduces an Article 11 workaround to ease trial delays. While improving mult...
Turning Patient Experience into Evidence: ACCGG Brings Gastric Cancer Voices into HTA Decisions
The Spanish Association Against Gastric Cancer and Gastrectomized Patients (ACCGG) has joined the IMPACTA HTA initiative to ensure that patient exp...
BRAF-Mutated mCRC: The First-Line Breakthrough Patients Have Been Waiting For
New evidence from the BREAKWATER trial signals a major shift in treating BRAF-mutated metastatic colorectal cancer, moving targeted therapy into th...